THE ROLE OF CORNEAL COLLAGEN CROSS-LINKING IN KERATOCONUS MANAGEMENT: BASED ON ONE-CENTER EXPERIENCE IN SULAIMANI CITY, KURDISTAN REGION-IRAQ
DOI:
https://doi.org/10.17656/jsmc.10278Keywords:
Corneal Cross-linking, Thinnest location of cornea, K1, Fattest meridian, K2, Steepest meridian D, Diopter, Efficacy, KeratoconusAbstract
Background
Corneal Collagen Cross-Linking has a major role in the management of keratoconus.
Objectives
Determining the effectiveness of Corneal Cross-linking, using Corneal Topography and tomography, with progressive Keratoconus.
Materials and Methods
The study conducted at Soma Eye Center, Sulaimani City, Kurdistan-Iraq, six months from September 2018 to March 2019. A total of 34 eyes of 20 patients with progressive bilateral Keratoconus. Each patient sought written informed consent, which was accompanied by corneal cross-linking with the riboflavin topical eye drops. Patients were followed up the for 6 months and corneal topography and tomography was replicated and recorded.
Results
The patients ‘ age was between 12 and 35 years. There were 12 females and 8 males. The change in post procedure K1 was statistically significant at the significant level of 0.05 as the p-value was 0.029. For the post procedure K2 the same can be noticed as the p value was 0.0. In addition post procedure central corneal thickness change was remarkable, the mean change in central corneal thickness was about 10.14µ, and this change was significant at the statistical level of 0.05, because the P value was 0.00. Changes in keratometry, was more significant for female than male both for K1 and K2, mean K1 change for males was 0.05 and for females was 0.2, the same result can be viewed for the post procedure change in K2, mean change for males was 0.6 while for females was 0.8. These changes were more significant in female than in male. P values were 0.01 and 0.00 respectively.
Conclusion
In patients with progressive Keratoconus within six months of follow-up it has been demonstrated that corneal cross-linking is effective for inducing regression or halting progression of disease, while the effectiveness of the corneal cross-linking has been affected by patients’ gender but not by age.
References
Niknam S, Shamshiri M, Shahrzad SS. Treatment of moderate to severe keratoconus with 6-mm Intacs SK. Int J Ophthalmol. 2012; 5(4):513–516.
Raiskup-Wolf F, Hoyer A, Spoerl E. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus:long-term results. J Cataract Refract Surg. 2008;34(5):796–801. DOI: https://doi.org/10.1016/j.jcrs.2007.12.039
Sedghipour MR, Sadigh AL, Motlagh BF. Revisiting corneal topography for the diagnosis of keratoconus:use of Rabinowitz's KISA% index. Clin Ophthalmol. 2012;6:181–184. DOI: https://doi.org/10.2147/OPTH.S24219
Asri D, Touboul D, Fournié P. Corneal collagen crosslinking in progressive keratoconus:multicenter results from the French National Reference Center for Keratoconus. J Cataract Refract Surg. 2011;37(12):2137–2143. DOI: https://doi.org/10.1016/j.jcrs.2011.08.026
Tan P, Mehta JS. Collagen crosslinking for keratoconus. J Ophthalmic Vis Res. 2011;6(3):153–154.
Li G, Fan ZJ, Peng XJ. Corneal collagen crosslinking for conical ectasia of post-LASIK:one-year results. Int J Ophthalmol. 2012;5(2):190–195.
Agrawal V. Long-term results of cornea collagen crosslinking with riboflavin for Keratoconus. Indian J Ophthalmol. 2013;61(8):433–434. DOI: https://doi.org/10.4103/0301-4738.116072
Wollensak G, Aurich H, Wirbelauer C. Potential use of riboflavin/UVA crosslinking in bullous keratopathy. Ophthalmic Res. 2009;41:114–117. doi:10.1159/000187630. DOI: https://doi.org/10.1159/000187630
Sharma N, Roy S, Maharana PK. Outcomes of corneal collagen crosslinking inpseudophakic bullous keratopathy. Cornea. 2014;33(3):243–246. doi:10.1097/ICO.0000000000000004. DOI: https://doi.org/10.1097/ICO.0000000000000004
Krueger RR, Ramos-Esteban JC. Staged intrastromal delivery of riboflavin with UVA crosslinking in advanced bullous keratopathy:laboratory investigationand first clinical case. J Refract Surg. 2008;24(7):S730–S736. doi:10.3928/1081597x-20080901-17 DOI: https://doi.org/10.3928/1081597X-20080901-17
Ucakhan OO, Saglik A. Outcome of two Corneal Collagen Crosslinking methods in Bullous Keratopathy dueto Fuchs'Endothelial Dystrophy. Case Rep Med 2014. 2014:463905. doi:10.1155/2014/463905. DOI: https://doi.org/10.1155/2014/463905
O'Brart DPS, Chan E, Samaras K. A randomized, prospective study to investigate the efficacy of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linkage to halt the progression of keratoconus. Br J Ophthalmol. 2011;95(11):1519–1524. [PubMed]. DOI: https://doi.org/10.1136/bjo.2010.196493
Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan. A randomized controlled trial of corneal collagen crosslinking in progressive keratoconus: preliminary results. J Refract Surg. 2008;24(7):S720–S725. [PubMed] DOI: https://doi.org/10.3928/1081597X-20080901-15
Georgiou T, Funnell CL, Cassels-Brown A. Influence of Ethnic Origin on the Incidence of Keratoconus and Associated Atopic Disease in Asians and White Patients. Eye (Lond.) 2004; 18(4):379–383. [PubMed] DOI: https://doi.org/10.1038/sj.eye.6700652
Tuft SJ, Moodaley LC, Gregory WM. Prognostic Factors for the Progression of Keratoconus. Ophthalmology. 1994; 101(3):439–447. [PubMed] DOI: https://doi.org/10.1016/S0161-6420(94)31313-3
Baenninger, P. B., Bachmann, L. M., Wienecke. (2014). Effects and adverse events after CXL for keratoconus are independent of age: a 1-year follow-up study. Eye (London, England), 28(6), 691–695. doi:10.1038/eye.2014.56 DOI: https://doi.org/10.1038/eye.2014.56
Toprak, I., Yaylalı, V., & Yildirim, C. (2014). Factors affecting outcomes of corneal collagen crosslinking treatment. Eye (London, England), 28(1), 41–46. doi:10.1038/eye.2013.224 DOI: https://doi.org/10.1038/eye.2013.224
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Kosar Ali Rashid
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This work is licensed under 